Tagliari Ana Paula, Petersen Saadi Rodrigo, Keller Saadi Eduardo
Post Graduate Program in Cardiology and Cardiovascular Science, Federal University of Rio Grande do Sul, Porto Alegre 90035-002, Brazil.
Cardiovascular Surgery Department, Hospital São Lucas da PUC-RS, Porto Alegre 90619-900, Brazil.
J Clin Med. 2022 Sep 1;11(17):5181. doi: 10.3390/jcm11175181.
Transcatheter aortic valve implantation (TAVI) to treat patients with severe symptomatic aortic stenosis is a well-established procedure. Even though cases series have reported TAVI use in high-risk patients with pure native aortic regurgitation, this is still considered an off-label intervention, especially when the aortic annulus dimensions are beyond the recommended by prosthesis manufacturers. Herein, we provide an updated review regarding the transcatheter treatment of pure native aortic regurgitation and illustrate this issue by presenting a clinical case of a patient with pure aortic regurgitation and a large aortic annulus who received a self-expanding non-dedicated transcatheter heart valve.
经导管主动脉瓣植入术(TAVI)用于治疗有严重症状的主动脉瓣狭窄患者是一种成熟的手术。尽管病例系列报道了TAVI在高危单纯原发性主动脉瓣反流患者中的应用,但这仍被视为一种超适应证干预,尤其是当主动脉瓣环尺寸超出假体制造商推荐范围时。在此,我们提供了关于单纯原发性主动脉瓣反流经导管治疗的最新综述,并通过展示一例单纯主动脉瓣反流且主动脉瓣环较大的患者接受自膨胀非专用经导管心脏瓣膜治疗的临床病例来说明这一问题。